FORM 3A - Director/Chief Executive Notice - Interests in Shares of Listed Corporation
 
Form Serial Number: DA20240521E00275
1. Date of relevant event: 08/05/2024
(dd/mm/yyyy)
2. Date when director became aware of the relevant event/ interest in the shares (if later):
(dd/mm/yyyy)
3. Stock code: 06990
4. Name of listed corporation: 四川科倫博泰生物醫藥股份有限公司 - B - H股 
5. Class of shares: Others 
6. Number of issued shares in class: 92,571,094
7. Name of director (English) as printed on HKID Card/Passport:
(Surname) LIU
(Other names) Gexin
10. Name of director (Chinese): 刘革新 
11. Chinese Character Code as printed on HKID Card:
 
24. Details of relevant event:
  Brief description of relevant event Capacity in which shares were/are held Number of shares bought/sold or involved Currency of transaction On Exchange Off Exchange
Before relevant event After relevant event Highest price (per share) Average price (per share) Average consideration (per share) Consideration code
Long position 
1101The number of shares in which you are interested has increased because:
you purchased the shares
 
 
2201Interest of corporation controlled by you
 		 4,423,870  CNY      136.2100 
3101Cash
 
Short position 
 
 
 		            
 
25. Total shares in listed corporation immediately before the relevant event:
 Total number of sharesPercentage figure (%)
Long position78,777,84285.10
 
26. Total shares in listed corporation immediately after the relevant event:
 Total number of sharesPercentage figure (%)
Long position83,201,71285.78
 
27. Capacity in which interests disclosed in Box 26 are held:
Code describing capacityNumber of shares
2201Interest of corporation controlled by you
Long position83,201,712
 
28. Further information in derivative interests in listed corporation :
Derivatives code Exercise period (dd/mm/yyyy) Consideration - if derivatives granted by listed corporation Number of shares
  BeginsEndsCurrencyPrice for grantCurrencyExercise priceCurrencyPrice on assignment 
           
 
29. Further information in relation to interests of children under 18 and/or spouse:
Child/SpouseName of child/spouseNumber of shares
 
 
30. Further information in relation to interests of corporations controlled by Director:
Name of controlled corporationAddress and place of incorporationName of controlling person% controlDirect interest (Y/N)Number of shares
四川科伦药业股份有限公司中国成都市新都卫星城工业开发区南二路 （中国）刘革新23.67Y
Long position62,201,712
四川科伦药业股份有限公司中国成都市新都卫星城工业开发区南二路 （中国）刘革新23.67N
Long position21,000,000
成都科伦晶川科技有限公司中国成都市温江区成都海峡两岸科技产业开发园新华大道666号（中国）四川科伦药业股份有限公司100.00N
Long position21,000,000
成都科伦汇才企业管理中心(有限合伙)中国成都市温江区成都海峡两岸科技产业开发园新华大道666号（中国）成都科伦晶川科技有限公司(作为普通合伙人)100.00Y
Long position5,250,000
成都科伦汇德企业管理中心(有限合伙)中国成都市温江区成都海峡两岸科技产业开发园新华大道666号（中国）成都科伦晶川科技有限公司(作为普通合伙人)100.00Y
Long position5,250,000
成都科伦汇能企业管理中心(有限合伙)中国成都市温江区成都海峡两岸科技产业开发园新华大道666号（中国）成都科伦晶川科技有限公司(作为普通合伙人)100.00Y
Long position5,250,000
成都科伦汇智企业管理中心(有限合伙)中国成都市温江区成都海峡两岸科技产业开发园新华大道666号（中国）成都科伦晶川科技有限公司(作为普通合伙人)100.00Y
Long position5,250,000
 
31. Further information in relation to interests held by Director jointly with another person:
Name of joint shareholderAddressNumber of shares
 
 
32. Further information from a director who is a trustee, or beneficiary of a trust, or a person who has set up a Discretionary Trust:
Names of TrustAddressStatus codeNumber of shares
  
 
33. Further information from a party to an agreement under Section 317 (Please see Notes for further information required):
Names of other partiesAddressNumber of shares
 
Total number of shares in which a director is interested under sections 317 and 318
 
34. Supplementary information: 根据科伦药业与科伦博泰签署的定向发行股份认购协议，科伦药业拟认购科伦博泰4,423,870股，刘革新先生通过控制的法团科伦药业持有的科伦博泰H股股份数量及占比相应上升。该次认购待科伦博泰股东大会审议通过、中国证监会注册等生效条件完成后生效。就方格26而言，有关百分比是参照完成认购后的未上市股份总数（即96,994,964）计算。
35. Log/Serial Number of the previous form:
36. Number of concert party document(s) under section 317 attached/uploaded:
Date of filing this Form 3A: 21/05/2024
(dd/mm/yyyy)